What is Biospatial?
Headquartered in Research Triangle Park, North Carolina, Biospatial operates at the intersection of healthcare technology and big data. The company maintains a sophisticated data network that provides near real-time access to electronic patient care reports (ePCR) from thousands of Emergency Medical Services providers across more than 40 states. By synthesizing a database of over 100 million ePCRs with diverse healthcare datasets, Biospatial enables its enterprise clients to enhance situational awareness and improve clinical outcomes. Its proprietary AI-driven platform serves as a foundational tool for organizations requiring high-fidelity, time-sensitive health information to inform complex decision-making processes.
How much funding has Biospatial raised?
Biospatial has raised a total of $3.4M across 1 funding round:
Series A
$3.4M
Series A (2022): $3.4M with participation from Gratus Private Capital, Front Porch Ventures, East Carolina Angels, and Cofounders Capital
Key Investors in Biospatial
Cofounders Capital
Cofounders Capital is a venture capital fund that specializes in seed stage investments, focusing primarily on B2B software companies located in the Southeast region.
East Carolina Angels
An angel investment group dedicated to supporting early-stage companies and fostering innovation within the North Carolina business ecosystem.
Front Porch Ventures
A diversified investment entity that engages in various property and business ventures, providing strategic backing to emerging enterprises.
What's next for Biospatial?
With the successful closure of this major strategic investment, Biospatial is well-positioned to accelerate its product development roadmap and deepen its penetration into the enterprise healthcare market. The company's trajectory suggests a focus on enhancing the predictive capabilities of its AI models, which are essential for identifying public health trends and optimizing resource allocation for EMS agencies. As the demand for real-time health data continues to surge, Biospatial is expected to leverage its unique data moat to forge new partnerships and expand its influence in the broader health-tech landscape, ensuring that its stakeholders remain at the forefront of data-driven medical intelligence.
See full Biospatial company page
